# Clinical Trials Data EGFR - Document 60

# Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

## Clinical Trial: https://clinicaltrials.gov/study/NCT01665417

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Pathologic confirmation of lung adenocarcinoma with measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded on CT); Patients must have previously untreated locally advanced or metastatic NSCLC; Patients must have lung cancer with a documented EGFR activating mutation (exon 19 deletion, L858R).\n\nExclusion Criteria:\n\n\* Prior chemotherapy Prior treatment with gefitinib, erlotinib, or other drugs that target EGFR Patients must not be receiving any other investigational agents Any evidence of interstitial lung disease",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, a patient with an EGFR gene mutation would be eligible for the trial, provided the mutation is an activating mutation such as an exon 19 deletion or L858R. Additionally, the patient must meet other inclusion criteria, such as having untreated locally advanced or metastatic non-small cell lung cancer (NSCLC) and measurable disease. They must also not meet any exclusion criteria, such as having had prior chemotherapy or prior treatment with drugs that target EGFR like gefitinib or erlotinib.